Indications for Renal Artery Stenting
DOI:
https://doi.org/10.2015/hc.v3i1%20sup.158Keywords:
Renal artery stenosis, fibromuscular dysplasia, interventional treatment, renovascular hypertension, pulmonary edema, renal insufficiencyAbstract
Renal artery stenosis (RAS) is a relatively common condition in the elderly, especially in the setting of concomitant vascular disease in other anatomical sites and is most often of atheromatous origin. Rarely is it encountered in young women as a result of fibromuscular dysplasia. RAS is considered responsible for refractory or accelerated hypertension, progressive loss of renal function and deterioration of patients??? cardiovascular status, with episodes of angina or pulmonary oedema disproportional to the extent of coronary artery disease and left ventricle functional capacity, dominating the clinical presentation. This article summarizes the pathophysio logical implications and diagnostic methods and attempts a review of the current literature on indications and efficacy of the available therapeutic options for RAS, focusing on interventional treatment. Renal artery stenosis (RAS) is most commonly due to atherosclerosis (???90%) or fibromuscular dysplasia (10%) and rarely to extrinsic compression, neurofibromatosis type I or Williams syndrome. Fibromuscular dysplasia predominates in young women (30-50 years old), is a nonatherosclerotic, noninflammatory vascular disease that causes stenosis in medium and small arteries, most commonly involving the distal 2/3 of the renal artery and carotid arteries. Atherosclerotic renal artery stenosis is usually encountered in males over 55 years old and often occurs at the ostium or the proximal 2 cm of the artery. [1,2] Refractory hypertension, progressive renal function deterioration and recurrent episodes of decompensated heart failure or flash pulmonary oedema are the most common clinical manifestations of the disease Both conservative and interventional treatment have been proposed and applied with comparable efficacy, as far as atherosclerotic disease is concerned and thus certain controversies have arisen regarding the treatment of choice.[3]Downloads
Issue
Section
License
Authors who publish with this journal agree to the following terms:a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).